Antigenicity and infectivity characterisation of SARS-CoV-2 BA.2.86
Description
No abstract
PubMed COVID-19 Clinical Care
2531 - 2540 of 6604 results found
Achieving Sustainable Health Equity Locally After the COVID-19 Emergency Response
Description
No abstract
A systematic review and meta-analysis of the efficacy of N95 respirators and surgical masks for protection against COVID-19
Description
Former meta-analyses concluded that there was not sufficient evidence to determine the effect of surgical masks and N95 respirators. We collected randomized controlled trials (RCTs) and conducted a systematic review and meta-analysis to evaluate the
An Innovative AI-based primer design tool for precise and accurate detection of SARS-CoV-2 variants of concern
Description
As the COVID-19 pandemic winds down, it leaves behind the serious concern that future, even more disruptive pandemics may eventually surface. One of the crucial steps in handling the SARS-CoV-2 pandemic was being able to detect the presence of the
A proofreading mutation with an allosteric effect allows a cluster SARS-CoV-2 viruses to rapidly evolve
Description
The RNA dependent RNA polymerase (RdRp) of the SARS-CoV-2 virus is error prone, with errors being corrected by the exonuclease (NSP14) proofreading mechanism. However, the mutagenesis and subsequent evolutionary trajectory of the virus is mediated by
A multivariable model of barriers to COVID-19 vaccination: Using cross sectional data from a nationally distributed survey in the United States
Description
CONCLUSIONS: Discrimination overall remained a significant barrier to vaccination, while nativity was not significant when accounting for socioeconomic and sociodemographic factors. Discrimination must become a public health priority in addressing
A viral RNA-dependent RNA polymerase inhibitor VV116 broadly inhibits human coronaviruses and has synergistic potency with 3CLpro inhibitor nirmatrelvir
Description
During the ongoing pandemic, providing treatment consisting of effective, low-cost oral antiviral drugs at an early stage of SARS-CoV-2 infection has been a priority for controlling COVID-19. Although Paxlovid and molnupiravir have received emergency
An Early Epidemiological Investigation of COVID-19 in Parsa, Nepal
Description
No abstract